SICCARDI, MARCO

SICCARDI, MARCO  

Dip. DISCIPLINE MEDICO CHIRURGICHE (attivo dal 01/01/1900 al 30/04/2013)  

Mostra records
Risultati 1 - 20 di 75 (tempo di esecuzione: 0.052 secondi).
Titolo Data di pubblicazione Autore(i) File
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 2010 Calcagno A; Milia MG; D'Avolio A; Ndayishimiyae P; Dusabimana P; Bonora S; Cusato J; Simiele M; Rostagno R; Siccardi M; Audagnotto S; Ghisetti V; Di Perri G.
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 2011 A. D'Avolio;M. Simiele;M. Siccardi;L. Baietto;M. Sciandra;V. Oddone;F. R. Stefani;S. Agati;J. Cusato;S. Bonora;G. Di Perri
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients 2008 Antonio D'Avolio; Mauro Sciandra; Marco Siccardi; Lorena Baietto; Daniel Gonzalez de; Stefano Bonora; Giovanni Di Perri
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 2008 Bonora S; D'Avolio A; Tettoni C; Siccardi M; Gonzalez de Requena D; Baietto L; Cometto C; Sciandra M; Trentini L; Di Perri G.
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 2009 Schipani A; Siccardi M; D'Avolio A; Baietto L; Calcagno A; Tettoni C; Bonora S; Davis G; Khoo S; Back DJ; Di Perri G; Owen A
A Population Pharmacokinetic Model Illustrates an Association Between a Pregnane-X-Receptor (PXR) Polymorphism and Boosted Atazanavir Clearance 2010 Schipani A; Siccardi M; Boffito M; D’Avolio A; Bonora S; Davies G; Khoo S; Back D; Di Perri G; Owen A
A Simple and Fast Method for Quantification of Ertapenem using Meropenem as Internal Standard in Human Plasma in a Clinical Setting 2008 D'AVOLIO A; BAIETTO L; DE ROSA FG; GARAZZINO S; SCIANDRA M; SICCARDI M; BONORA S; DI PERRI G
A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method 2007 D'AVOLIO A; SCIANDRA M; SICCARDI M; BAIETTO L; DE REQUENA DG; BONORA S; DI PERRI G
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 2010 A. D'Avolio;M. Simiele;L. Baietto;M. Siccardi;M. Sciandra;S. Patanella;S. Bonora;G. Di Perri
ABCB1 3435C>T e CYP2B6 516G>T possono predire le concentrazioni plasmatiche ottimali di Nevirapina 2009 Antonio D'Avolio; Marco Siccardi; Deborah Gatti; Lorena Baietto; Francesca Romana Stefani; Marco Simiele; Mauro Sciandra; Stefano Bonora; Giovanni Di Perri
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 2008 Antonio Dʼavolio; Lorena Baietto; Marco Siccardi; Mauro Sciandra; Marco Simiele; Valentina Oddone; Stefano Bonora; Giovanni Di Perri
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 2010 Bonora S; Calcagno A; Viganò O; Bigliano P; Rusconi S; Trentini L; Tettoni MC; Orofino G; Salassa B; Bramato C; D'Avolio A; Siccardi M; Colella E; Galli M; Di Perri G
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 2010 Marco Simiele; Antonio D’Avolio; Marco Siccardi; Lorena Baietto; Francesca Romana Stefani; Silvia Agati; Jessica Cusato; Mauro Sciandra; Stefano Bonora; Giovanni Di Perri
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir 2008 Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Sara Gibbons; Mauro Sciandra; Daniela Colucci; Stefano Bonora; Saye Khoo; David J Back; Giovanni Di Perri; Andrew Owen
Ceftriaxone bone penetration in patients with septic non-union of the tibia 2011 Garazzino S; Aprato A; Baietto L; D'Avolio A; Maiello A; De Rosa FG; Aloj D; Siccardi M; Biasibetti A; Massè A; Di Perri G.
Class-specific relative genetic contribution for key antiretroviral drugs 2015 Siccardi, Marco; Olagunju, Adeniyi; Simiele, Marco; D'Avolio, Antonio; Calcagno, Andrea; Di Perri, Giovanni; Bonora, Stefano; Owen, Andrew
Combined effect of SLCO1B1 521T>C, PXR 63396C>T, and ABCB1 3435C>T on the achievement of therapeutic concentrations of unboosted Atazanavir 2009 M. Siccardi; A. D’Avolio; S. Bonora; L. Baietto; D. Gatti; A. Calcagno; V. Ghisetti; M. Lanzafame; G. Penco; D. Back; A. Owen; G. Di Perri
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 2012 Calcagno A;Yilmaz A;Cusato J;Simiele M;Bertucci R;Siccardi M;Marinaro L;D'Avolio A;Di Perri G;Bonora S
Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. 2010 L. Baietto;A. D'Avolio;F. G. De Rosa;S. Garazzino;M. Michelazzo;G. Ventimiglia;M. Siccardi;M. Simiele;M. Sciandra;G. Di Perri
Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. 2010 L. Baietto;A. D'Avolio;G. Ventimiglia;F. G. De Rosa;M. Siccardi;M. Simiele;M. Sciandra;G. Di Perri